Johnson & Johnson (NYSE:JNJ) Stock Unloaded Rep. C. Scott Franklin

Representative C. Scott Franklin (R-Florida) recently sold shares of Johnson & Johnson (NYSE:JNJ). In a filing disclosed on July 14th, the Representative disclosed that they had sold between $15,001 and $50,000 in Johnson & Johnson stock on June 16th. The trade occurred in the Representative’s “FIDELITY JOINT TBE” account.

Representative C. Scott Franklin also recently made the following trade(s):

• Sold $15,001 – $50,000 in shares of Visa (NYSE:V) on 6/16/2025.
• Sold $15,001 – $50,000 in shares of Apple (NASDAQ:AAPL) on 6/16/2025.
• Sold $1,001 – $15,000 in shares of Alphabet (NASDAQ:GOOG) on 6/16/2025.
• Sold $1,001 – $15,000 in shares of Merck & Co., Inc. (NYSE:MRK) on 6/16/2025.
• Sold $15,001 – $50,000 in shares of McDonald’s (NYSE:MCD) on 6/16/2025.
• Sold $1,001 – $15,000 in shares of United Parcel Service (NYSE:UPS) on 6/16/2025.
• Sold $15,001 – $50,000 in shares of Walmart (NYSE:WMT) on 6/16/2025.
• Sold $15,001 – $50,000 in shares of Berkshire Hathaway (NYSE:BRK.B) on 6/16/2025.
• Sold $15,001 – $50,000 in shares of Home Depot (NYSE:HD) on 6/16/2025.
• Sold $1,001 – $15,000 in shares of Kenvue (NYSE:KVUE) on 6/16/2025.

Johnson & Johnson Stock Up 0.4%

JNJ stock opened at $163.65 on Friday. Johnson & Johnson has a twelve month low of $140.68 and a twelve month high of $169.99. The company has a quick ratio of 1.03, a current ratio of 1.26 and a debt-to-equity ratio of 0.49. The firm has a market capitalization of $393.75 billion, a PE ratio of 17.50, a PEG ratio of 2.18 and a beta of 0.41. The stock has a 50-day simple moving average of $154.29 and a two-hundred day simple moving average of $154.97.

Johnson & Johnson (NYSE:JNJ) last announced its earnings results on Wednesday, July 16th. The company reported $2.77 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.68 by $0.09. Johnson & Johnson had a net margin of 25.00% and a return on equity of 33.07%. The business had revenue of $23.74 billion during the quarter, compared to analyst estimates of $22.85 billion. During the same period in the previous year, the business posted $2.82 earnings per share. Johnson & Johnson’s revenue for the quarter was up 5.8% on a year-over-year basis. On average, equities analysts predict that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 9th. Shareholders of record on Tuesday, August 26th will be issued a dividend of $1.30 per share. This represents a $5.20 dividend on an annualized basis and a yield of 3.18%. The ex-dividend date is Tuesday, August 26th. Johnson & Johnson’s payout ratio is presently 55.61%.

Institutional Trading of Johnson & Johnson

A number of institutional investors have recently made changes to their positions in the stock. EWA LLC boosted its stake in shares of Johnson & Johnson by 26.8% during the second quarter. EWA LLC now owns 2,860 shares of the company’s stock valued at $437,000 after purchasing an additional 604 shares during the period. Philip James Wealth Mangement LLC boosted its stake in shares of Johnson & Johnson by 13.5% during the second quarter. Philip James Wealth Mangement LLC now owns 87,853 shares of the company’s stock valued at $13,420,000 after purchasing an additional 10,438 shares during the period. Gold Investment Management Ltd. lifted its stake in Johnson & Johnson by 1.5% in the second quarter. Gold Investment Management Ltd. now owns 18,790 shares of the company’s stock worth $2,914,000 after acquiring an additional 279 shares during the period. Naples Global Advisors LLC lifted its stake in Johnson & Johnson by 3.5% in the second quarter. Naples Global Advisors LLC now owns 48,414 shares of the company’s stock worth $7,395,000 after acquiring an additional 1,655 shares during the period. Finally, Pure Financial Advisors LLC lifted its stake in Johnson & Johnson by 40.9% in the second quarter. Pure Financial Advisors LLC now owns 28,037 shares of the company’s stock worth $4,283,000 after acquiring an additional 8,140 shares during the period. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Analyst Ratings Changes

JNJ has been the subject of several research analyst reports. Wall Street Zen lowered shares of Johnson & Johnson from a “strong-buy” rating to a “buy” rating in a research report on Friday. Raymond James Financial dropped their target price on shares of Johnson & Johnson from $165.00 to $162.00 and set an “outperform” rating for the company in a research report on Monday, April 14th. Benchmark upgraded shares of Johnson & Johnson to a “strong-buy” rating in a research report on Thursday, April 24th. Leerink Partners lowered Johnson & Johnson from an “outperform” rating to a “market perform” rating and cut their target price for the stock from $169.00 to $153.00 in a research note on Tuesday, May 13th. Finally, The Goldman Sachs Group raised Johnson & Johnson from a “neutral” rating to a “buy” rating and upped their target price for the stock from $157.00 to $172.00 in a research note on Wednesday, April 9th. Eleven equities research analysts have rated the stock with a hold rating, nine have assigned a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $172.87.

About Representative Franklin

Scott Franklin (Republican Party) is a member of the U.S. House, representing Florida’s 18th Congressional District. He assumed office on January 3, 2023. His current term ends on January 3, 2027.

Franklin (Republican Party) is running for re-election to the U.S. House to represent Florida’s 18th Congressional District. He declared candidacy for the 2026 election.

Scott Franklin was born in Thomaston, Georgia. Franklin graduated from Lakeland High School. He served in the U.S. Navy from 1986 to 2000 and the U.S. Navy Reserve from 2000 to 2012.

Franklin earned a B.S. from the United States Naval Academy in 1986 and an M.B.A. from Embry-Riddle Aeronautical University in 1994. Franklin’s career experience includes owning an insurance agency and working as a naval aviator with the U.S. Navy.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.